Summary | |
---|---|
Symbol | NADK |
Name | NAD kinase |
Aliases | FLJ13052; dJ283E3.1; poly(P)/ATP NAD kinase |
Chromosomal Location | 1p36.33 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | - |
Domain |
PF01513 ATP-NAD kinase |
Function |
- |
Biological Process |
GO:0006732 coenzyme metabolic process GO:0006733 oxidoreduction coenzyme metabolic process GO:0006739 NADP metabolic process GO:0006741 NADP biosynthetic process GO:0009108 coenzyme biosynthetic process GO:0009116 nucleoside metabolic process GO:0009119 ribonucleoside metabolic process GO:0009123 nucleoside monophosphate metabolic process GO:0009126 purine nucleoside monophosphate metabolic process GO:0009141 nucleoside triphosphate metabolic process GO:0009144 purine nucleoside triphosphate metabolic process GO:0009150 purine ribonucleotide metabolic process GO:0009161 ribonucleoside monophosphate metabolic process GO:0009165 nucleotide biosynthetic process GO:0009167 purine ribonucleoside monophosphate metabolic process GO:0009199 ribonucleoside triphosphate metabolic process GO:0009205 purine ribonucleoside triphosphate metabolic process GO:0019359 nicotinamide nucleotide biosynthetic process GO:0019362 pyridine nucleotide metabolic process GO:0019363 pyridine nucleotide biosynthetic process GO:0019674 NAD metabolic process GO:0042278 purine nucleoside metabolic process GO:0046034 ATP metabolic process GO:0046128 purine ribonucleoside metabolic process GO:0046496 nicotinamide nucleotide metabolic process GO:0051186 cofactor metabolic process GO:0051188 cofactor biosynthetic process GO:0072524 pyridine-containing compound metabolic process GO:0072525 pyridine-containing compound biosynthetic process GO:1901293 nucleoside phosphate biosynthetic process GO:1901657 glycosyl compound metabolic process |
Molecular Function |
GO:0003951 NAD+ kinase activity |
Cellular Component | - |
KEGG |
hsa00760 Nicotinate and nicotinamide metabolism hsa01100 Metabolic pathways |
Reactome |
R-HSA-1430728: Metabolism R-HSA-196854: Metabolism of vitamins and cofactors R-HSA-196849: Metabolism of water-soluble vitamins and cofactors R-HSA-196807: Nicotinate metabolism |
Summary | |
---|---|
Symbol | NADK |
Name | NAD kinase |
Aliases | FLJ13052; dJ283E3.1; poly(P)/ATP NAD kinase |
Chromosomal Location | 1p36.33 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between NADK and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | NADK |
Name | NAD kinase |
Aliases | FLJ13052; dJ283E3.1; poly(P)/ATP NAD kinase |
Chromosomal Location | 1p36.33 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of NADK in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | NADK |
Name | NAD kinase |
Aliases | FLJ13052; dJ283E3.1; poly(P)/ATP NAD kinase |
Chromosomal Location | 1p36.33 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of NADK in various data sets.
|
Points in the above scatter plot represent the mutation difference of NADK in various data sets.
|
Summary | |
---|---|
Symbol | NADK |
Name | NAD kinase |
Aliases | FLJ13052; dJ283E3.1; poly(P)/ATP NAD kinase |
Chromosomal Location | 1p36.33 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NADK. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | NADK |
Name | NAD kinase |
Aliases | FLJ13052; dJ283E3.1; poly(P)/ATP NAD kinase |
Chromosomal Location | 1p36.33 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NADK. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NADK. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | NADK |
Name | NAD kinase |
Aliases | FLJ13052; dJ283E3.1; poly(P)/ATP NAD kinase |
Chromosomal Location | 1p36.33 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NADK. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | NADK |
Name | NAD kinase |
Aliases | FLJ13052; dJ283E3.1; poly(P)/ATP NAD kinase |
Chromosomal Location | 1p36.33 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of NADK expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | NADK |
Name | NAD kinase |
Aliases | FLJ13052; dJ283E3.1; poly(P)/ATP NAD kinase |
Chromosomal Location | 1p36.33 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between NADK and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |